Conclusion
This systematic review and meta-analysis shows that the use of
nortriptyline for smoking cessation resulted in higher prolonged abstinence
rates after at least 6 months compared to placebo treatment. Furthermore, the
use of nortriptyline for smoking cessation is well tolerated and safe. As a result,
we believe health care professionals should be recommended to prescribe
nortriptyline as a first-line therapy for smoking cessation, also because of the
much lower cost of nortriptyline compared to bupropion SR.